First Immunotherapy Approved for Patients with Small Cell Lung Cancer

Comments by David M. Waterhouse, MD, MPH, co-director of research with OHC. Article by Arthur N. Brodsky, PhD, Cancer Research Institute

On August 17, 2018 the FDA approved the first immunotherapy – the checkpoint inhibitor nivolumab (Opdivo) – for patients with small cell lung cancer (SCLC). This approval provides an important treatment option for patients with metastatic SCLC... Read More

Today, OHC’s James H. Essell, MD, a leading authority on blood and marrow transplant and a national expert leading the CAR T-cell therapy program for The US Oncology Network, was invited to spend time with emergency medicine residents at the... Read More

Are there other signs of breast cancer besides a lump?

Comments from Cynthia Chua, MD, OHC medical oncologist. Original article by Rachel Nall, RN, BSN, CCRN, Medical News Today.

A lump in the breast is just one of the possible signs of breast cancer in men or women. Sometimes there may be signs and symptoms of breast cancer without a noticeable lump in the breast. These symptoms may not be caused by cancer, but they might... Read More

Each year OHC (Oncology Hematology Care) and Cancer Support Community (CSC) bring together four “chefs” for fun, laughter and education as they battle their way to become the new Cancer Chopped Champion! This year marks the third annual Cancer... Read More

Could immunotherapy drug eliminate the recurrence of kidney cancer?

David M. Waterhouse, MD, MPH, Co-director of Research at OHC

The average age of people diagnosed with cancer of the kidneys (renal cell carcinoma) is 64. Once diagnosed, if caught early, the five-year survival rate is 81%. But, if the cancer is caught at a later stage, survival rates plummet to less than 10%.... Read More

Research Shows Potential New Strategy Against Thyroid Cancer

Science Daily with additional comments from Robert B. Barriger, MD, radiation oncologist with OHC

Anaplastic thyroid cancer is one of the least common but most aggressive forms of thyroid cancer. Add to that, it’s resistance to cancer treatments. Patients diagnosed with the disease have an average lifespan of about five months after diagnosis.... Read More

Lynch Syndrome: Is it a generational thing?

Mark E. Johns, MD, a medical oncologist/hematologist with OHC who specializes in colon cancer

Michele’s sister was diagnosed with colon cancer at age 33. Because her sister was so young, Michele’s doctor suggested she have a colonoscopy. The surgeon removed three pre-malignant tumors. Michele considers her sister and her doctors... Read More

OHC (Oncology Hematology Care) is partnering with the David Benzer Strike Out Fear Foundation and the Cincinnati Reds to help local cancer patients reduce their fear and anxiety as they face cancer. David Benzer was a long-time member of the... Read More

Penne For Your Thoughts on Pasta

John Sacco, MD, a radiation oncologist with OHC who is also board certified in Integrative and Holistic Medicine

I am a radiation oncologist who works with a team of cancer experts to treat patients with cancer. I’m also board certified in Integrative and Holistic Medicine, which means I believe in a person-centered, team-based approach to health care. One... Read More

Don’t Let Acid Reflux Lead to Cancer

Joseph N. Shaughnessy, MD, radiation oncologist at OHC

According to the American College of Gastroenterology, 60 million Americans report having heartburn at least once a month, and some studies report that more than 15 million Americans have symptoms every day. Heartburn or acid indigestion is... Read More